Screener
ImmunityBio, Inc. IBRX Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProfitLoss.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total other expense, net | (562,997) | (65,471) |
| Loss before income taxes and noncontrolling interest | (632,788) | (129,900) |
| Income tax (expense) benefit | (9) | 234 |
| Net loss | (632,797) | (129,666) |
| Net loss attributable to noncontrolling interests, net of tax | (15) | (20) |
| Net loss attributable to ImmunityBio common stockholders | $(632,782) | $(129,646) |
| Net loss per ImmunityBio common share – basic and diluted | $(0.62) | $(0.15) |
| Weighted-average number of common shares used in computing net loss per share – basic and diluted | 1,026,874 | 853,162 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s net income?
- ImmunityBio, Inc. (IBRX) reported net income of -$632.8M in Q1 2026.
- How has ImmunityBio, Inc.'s net income changed year-over-year?
- ImmunityBio, Inc.'s net income decreased by 388.0% year-over-year, from -$129.67M to -$632.8M.
- What is the long-term trend for ImmunityBio, Inc.'s net income?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s net income has grown at a 0.1% compound annual growth rate (CAGR), from -$349.85M to -$351.47M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about ImmunityBio, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude